WTO TRIPS Agreement spurs innovation in the Indian biopharmaceutical industry
The upgrading of India’s IP laws as a result of its WTO commitments has confounded sceptics by encouraging its generics companies to move towards innovation.
Contributor
Assistant Professor of Healthcare Management at the School for Public Health and Primary Care (CAPHRI), Maastricht University
Dr. Federica Angeli is Assistant Professor of Healthcare Management at the School for Public Health and Primary Care (CAPHRI) at Maastricht University, the Netherlands.
She obtained her PhD in Business Administration from the University of Bologna, Italy, and has been Visiting Scholar at the Indian Institute of Management Bangalore (IIMB), India.
Her current research centres on inter-organizational strategies and networks, with a particular interest in the healthcare and biopharmaceutical sector.
Her work has been awarded prizes by the Academy of Management, Strategic Management Society and Academy of International Business.